Citadel Advisors LLC grew its position in ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 83.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 855,676 shares of the company's stock after purchasing an additional 389,247 shares during the quarter. Citadel Advisors LLC owned approximately 1.35% of ABIVAX Société Anonyme worth $6,264,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. abrdn plc grew its position in shares of ABIVAX Société Anonyme by 34.1% during the 4th quarter. abrdn plc now owns 424,181 shares of the company's stock worth $3,105,000 after buying an additional 107,750 shares during the period. JPMorgan Chase & Co. acquired a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $5,336,000. Guggenheim Capital LLC acquired a new stake in ABIVAX Société Anonyme during the fourth quarter worth about $92,000. Franklin Resources Inc. lifted its stake in ABIVAX Société Anonyme by 10.7% in the 4th quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company's stock valued at $10,732,000 after purchasing an additional 141,710 shares during the last quarter. Finally, Allostery Investments LP acquired a new stake in ABIVAX Société Anonyme during the 4th quarter valued at approximately $4,328,000. Institutional investors and hedge funds own 47.91% of the company's stock.
Analysts Set New Price Targets
ABVX has been the topic of a number of research analyst reports. JMP Securities restated a "market outperform" rating and issued a $33.00 target price on shares of ABIVAX Société Anonyme in a research note on Wednesday, April 30th. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th.
Read Our Latest Research Report on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Up 0.3%
ABVX traded up $0.02 on Wednesday, reaching $5.82. The stock had a trading volume of 129,146 shares, compared to its average volume of 133,878. ABIVAX Société Anonyme has a 12-month low of $4.77 and a 12-month high of $14.72. The business's 50-day moving average price is $6.39 and its two-hundred day moving average price is $7.19.
About ABIVAX Société Anonyme
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Stories
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
